Allgens(SH:688613) Sou Hu Cai Jing·2026-01-31 18:56Core Viewpoint - Aojing Medical (688613) has experienced a decline in stock price and is expected to report a mixed financial performance for 2025, with a projected net profit but also a loss when excluding non-recurring items. Group 1: Stock Performance - As of January 30, 2026, Aojing Medical's stock closed at 22.79 yuan, down 6.14% from the previous week's 24.28 yuan [1] - The stock reached a high of 24.9 yuan and a low of 22.45 yuan during the week [1] - The current market capitalization is 3.122 billion yuan, ranking 111 out of 127 in the medical device sector and 4579 out of 5184 in the A-share market [1] Group 2: Financial Performance Forecast - Aojing Medical forecasts a net profit attributable to shareholders of approximately 13.53 million yuan for the year 2025 [2][5] - The expected total revenue for 2025 is approximately 224 million yuan, representing a year-on-year growth of 8.48% [3][5][6] - The company anticipates a loss of about 514,700 yuan in net profit after excluding non-recurring items, although this reflects a significant reduction in losses compared to previous periods [4][6] Group 3: Factors Influencing Performance - The anticipated performance improvement is attributed to market opportunities arising from the centralized procurement of orthopedic artificial bones and the company's strengthened production assurance and marketing strategies [5]